Disease · MONDO_0000607

primary cutaneous T-cell non-Hodgkin lymphoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. primary cutaneous T-cell non-Hodgkin lymphoma. Diseases, record MONDO_0000607. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000607

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: primary cutaneous T-cell non-Hodgkin lymphoma; Open Targets
Open Targets ID: MONDO_0000607; Open Targets
Other names: CTCL, PCTCL, T-cell non-Hodgkin's lymphoma of skin, T-cell non-Hodgkin's lymphoma of the skin, cutaneous T cell lymphoma, cutaneous T-cell non-Hodgkin lymphoma, cutaneous T-cell non-Hodgkin's lymphoma, primary cutaneous T-cell non-Hodgkin's lymphoma, skin T-cell non-Hodgkin's lymphoma; Open Targets
Disease Ontology: DOID:0060061; Disease Ontology
MeSH: D016410; MeSH
NCI Thesaurus: C3467; NCI Thesaurus
Highest stage of its drugs: Approval, for 6 of its 105 drugs, from DailyMed, EMA Human Drugs, PMDA and TTD; Open Targets

Drugs105

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ROMIDEPSIN	CHEMBL343448	Protein	Approval	DailyMed and TTD	15	13	13	Drugs and targets
BEXAROTENE	CHEMBL1023	Small molecule	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	15	11	11	Drugs and targets
VORINOSTAT	CHEMBL98	Small molecule	Approval	DailyMed, PMDA and TTD	14	11	11	Drugs and targets
DENILEUKIN DIFTITOX	CHEMBL1201550	Protein	Approval	DailyMed and PMDA	9	7	7	Drugs and targets
METHOXSALEN	CHEMBL416	Small molecule	Approval	TTD	3	2	2	Drugs and targets
MECHLORETHAMINE HYDROCHLORIDE	CHEMBL1201001	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
MOGAMULIZUMAB	CHEMBL1743041	Antibody	Phase 3	ClinicalTrials.gov and TTD	12	11	11	Drugs and targets
BRENTUXIMAB VEDOTIN	CHEMBL1742994	Antibody drug conjugate	Phase 3	TTD	8	7	7	Drugs and targets
LENALIDOMIDE	CHEMBL848	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
BORTEZOMIB	CHEMBL325041	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets

1 to 10 of 105

See all 105 drugs

Targets154

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
HDAC1	Histone deacetylase	5	Histone deacetylase 1 inhibitor; Histone deacetylase inhibitor	Approval	https://conductscience.org/library/genes/3065	Drugs and targets
HDAC2	Histone deacetylase	5	Histone deacetylase 2 inhibitor; Histone deacetylase inhibitor	Approval	https://conductscience.org/library/genes/3066	Drugs and targets
HDAC3	Histone deacetylase	5	Histone deacetylase 3 inhibitor; Histone deacetylase inhibitor	Approval	https://conductscience.org/library/genes/8841	Drugs and targets
HDAC6	Histone deacetylase	5	Histone deacetylase 6 inhibitor; Histone deacetylase inhibitor	Approval	https://conductscience.org/library/genes/10013	Drugs and targets
HDAC10	Histone deacetylase	4	Histone deacetylase inhibitor	Approval	https://conductscience.org/library/genes/83933	Drugs and targets
HDAC11	Histone deacetylase	4	Histone deacetylase inhibitor	Approval	https://conductscience.org/library/genes/79885	Drugs and targets
HDAC4	Histone deacetylase	4	Histone deacetylase inhibitor	Approval	https://conductscience.org/library/genes/9759	Drugs and targets
HDAC5	Histone deacetylase	4	Histone deacetylase inhibitor	Approval	https://conductscience.org/library/genes/10014	Drugs and targets
HDAC7	Histone deacetylase	4	Histone deacetylase inhibitor	Approval	https://conductscience.org/library/genes/51564	Drugs and targets
HDAC8	Histone deacetylase	4	Histone deacetylase inhibitor	Approval	https://conductscience.org/library/genes/55869	Drugs and targets

1 to 10 of 154

See all 154 targets

Trials145

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01728805	Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL	Phase 3	372	2019-04-11	Cutaneous T-Cell Lymphoma	MOGAMULIZUMAB, VORINOSTAT	Its record names the disease	ClinicalTrials.gov
NCT02663518	A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors	Phase 1	249	2024-05-10	Hematologic Malignancies, Solid Tumor	NIVOLUMAB, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT02448381	FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)	Phase 3	169	2022-04-15	Cutaneous T-Cell Lymphoma	HYPERICIN	Its record names the disease	ClinicalTrials.gov
NCT02581631	An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas	Phase 1/2	145	2023-03-07	Non-Hodgkin's Disease	BRENTUXIMAB VEDOTIN, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT00425555	Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma	Phase 2	139	2021-08-16	Cutaneous T-Cell Lymphoma	PANOBINOSTAT	Its record names the disease	ClinicalTrials.gov
NCT00007345	Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma	Phase 2	131	2016-02-12	Cutaneous T Cell Lymphoma, Peripheral T Cell Lymphoma	ROMIDEPSIN	Its record names the disease	ClinicalTrials.gov
NCT01871727	A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma	Phase 3	112	2024-11-13	Persistent or Recurrent Cutaneous T-Cell Lymphoma	DENILEUKIN DIFTITOX	Its record names the disease	ClinicalTrials.gov
NCT00106431	A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)	Phase 2	102	2010-04-23	Cutaneous T-cell Lymphoma	ROMIDEPSIN	Its record names the disease	ClinicalTrials.gov
NCT03292406	A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)	Phase 2	86	2021-04-08	Cutaneous T Cell Lymphoma	RESIQUIMOD	Its record names the disease	ClinicalTrials.gov
NCT01007448	Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)	Phase 4	59	2019-11-12	Refractory Cutaneous T-cell Lymphoma	BEXAROTENE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 145

See all 145 trials

Comparisons in its trials29

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Bexarotene Exposed vs Bexarotene Naive: deaths from any cause	3 of 79	3 of 60	139	NCT00425555	Trial comparisons
Bexarotene Exposed vs Bexarotene Naive: serious adverse events	33 of 79	23 of 60	139	NCT00425555	Trial comparisons
Peripheral T-cell Lymphoma (PTCL) vs Cutaneous T-cell Lymphoma (CTCL): deaths from any cause	6 of 47	5 of 84	131	NCT00007345	Trial comparisons
Peripheral T-cell Lymphoma (PTCL) vs Cutaneous T-cell Lymphoma (CTCL): Number of Participants With Adverse Events	47 of 47	84 of 84	131	NCT00007345	Trial comparisons
Peripheral T-cell Lymphoma (PTCL) vs Cutaneous T-cell Lymphoma (CTCL): serious adverse events	20 of 47	38 of 84	131	NCT00007345	Trial comparisons
Bexarotene 150 mg/m^2/Day vs Bexarotene 300 mg/m^2/Day: serious adverse events	11 of 30	13 of 29	59	NCT01007448	Trial comparisons
Arm A (CTCL, ITT Population) vs Arm B (PTCL, ITT Population): serious adverse events	7 of 29	8 of 24	53	NCT00274651	Trial comparisons
Parts 2 and 3 : Cutaneous T-cell Lymphoma (CTCL) vs Parts 2 and 3: T-cell Lymphoma (TCL): Parts 2 and 3: Overall Response Rate (ORR)-Olsen 2011-Disease Indication	2 of 21	5 of 29	50	NCT02663518	Trial comparisons
Selinexor (PTCL) vs Selinexor (CTCL): Best Overall Response: Not Evaluable (NE)	4 of 9	2 of 7	16	NCT02314247	Trial comparisons
Selinexor (PTCL) vs Selinexor (CTCL): Best Overall Response: Progressive Disease (PD)	2 of 9	0 of 7	16	NCT02314247	Trial comparisons

1 to 10 of 29

See all 29 comparisons in its trials

Papers from its trials81

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31029646	RESULT	1	PubMed
29720488	RESULT	1	PubMed
29293620	RESULT	1	PubMed
29143824	RESULT	1	PubMed
28974506	RESULT	1	PubMed
28600132	RESULT	1	PubMed
28570279	RESULT	1	PubMed
28188133	RESULT	1	PubMed
28103725	RESULT	1	PubMed
27574190	RESULT	1	PubMed

1 to 10 of 81

See all 81 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0000607

GET https://conductscience.org/api/diseases/v1/MONDO_0000607/drugs?page=2

API reference For AI assistants